Get the Stockscreener App
5.02
1.57%
-0.08
Pre-market:
5.07
0.05
+1.00%
Acurx Pharmaceuticals Inc stock is traded at $5.02, with a volume of 121.92K.
It is down -1.57% in the last 24 hours and up +17.02% over the past month.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
See More
Previous Close:
$5.10
Open:
$5
24h Volume:
121.92K
Relative Volume:
0.25
Market Cap:
$7.96M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-4.3652
EPS:
-1.15
Net Cash Flow:
$-9.80M
1W Performance:
-22.89%
1M Performance:
+17.02%
6M Performance:
-41.63%
1Y Performance:
-86.65%
1-Day Range:
$4.91
$5.27
1-Week Range:
$4.91
$6.79
52-Week Range:
$3.80
$38.20
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
5.02 | 10.61M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
Will Acurx Pharmaceuticals Inc. (3ZO) stock draw ESG focused fundsMarket Movement Recap & Free Low Drawdown Momentum Trade Ideas - newser.com
Is Acurx Pharmaceuticals Inc. (3ZO) stock overpriced at current multiplesJuly 2025 Spike Watch & Growth Focused Investment Plans - newser.com
How strong is Acurx Pharmaceuticals Inc. (3ZO) stock earnings growthWeekly Trend Report & Fast Gain Stock Tips - newser.com
Can Acurx Pharmaceuticals Inc. stock attract ESG capital inflowsQuarterly Earnings Summary & Real-Time Volume Surge Alerts - newser.com
Can Acurx Pharmaceuticals Inc. stock sustain free cash flow growth2025 Price Momentum & Weekly High Return Forecasts - newser.com
Pattern recognition hints at Acurx Pharmaceuticals Inc. upsideGold Moves & Free Safe Capital Growth Stock Tips - newser.com
Why Acurx Pharmaceuticals Inc. stock appeals to analystsWeekly Investment Recap & Smart Investment Allocation Tips - newser.com
Will Acurx Pharmaceuticals Inc. stock outperform growth indexesMarket Trend Summary & Daily Oversold Stock Bounce Ideas - newser.com
What dividend safety score for Acurx Pharmaceuticals Inc. stockWeekly Stock Summary & Technical Buy Zone Confirmations - newser.com
Combining price and volume data for Acurx Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Trade Opportunity Analysis Reports - newser.com
Short Interest in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Grows By 82.1% - Defense World
How supply shortages influence Acurx Pharmaceuticals Inc. (3ZO) stock2025 Key Lessons & Risk Controlled Stock Alerts - newser.com
Multi factor analysis applied to Acurx Pharmaceuticals Inc.Recession Risk & Accurate Buy Signal Notifications - newser.com
What risks investors should watch in Acurx Pharmaceuticals Inc. stock2025 Market Outlook & Daily Profit Maximizing Trade Tips - newser.com
Can swing trading help recover from Acurx Pharmaceuticals Inc. lossesPortfolio Update Summary & Consistent Profit Trading Strategies - newser.com
Biodefense Market to Attain USD 32.87 Billion by 2034, Driven by Biotech Advancements and Government Funding - GlobeNewswire Inc.
Can Acurx Pharmaceuticals Inc. (3ZO) stock test all time highsBuy Signal & Fast Exit/Entry Strategy Plans - newser.com
Comparing Acurx Pharmaceuticals Inc. in custom built stock radarsDip Buying & Advanced Swing Trade Entry Alerts - newser.com
Can Acurx Pharmaceuticals Inc. stock sustain market leadershipTrade Risk Summary & Weekly Top Gainers Trade List - newser.com
Acurx Pharmaceuticals’ Ibezapolstat: Promising Preclinical and Clinical Efficacy Supports Buy Rating - TipRanks
Will Acurx Pharmaceuticals Inc. stock split attract more investors2025 Analyst Calls & Technical Pattern Alert System - newser.com
Is Acurx Pharmaceuticals Inc. stock recession proofQuarterly Profit Report & Expert Approved Momentum Ideas - newser.com
Acurx Pharmaceuticals Shareholders Approve Key Issuance Plans - MSN
Acurx Announces Phase 3-Ready Ibezapolstat Data at IDWeek 2025 | ACXP Stock News - Stock Titan
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):